Wednesday, September 27, 2023

No Result

View All Result

Media

No Result

View All Result

Commentary

Waiting for new drugs for rare disorders in Canada

September 6, 2023

Nigel Rawson

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

August 30, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

August 23, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

August 16, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

August 9, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

August 2, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

July 26, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

July 19, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

July 12, 2023

Time for the PMPRB to go: Nigel Rawson and Brett Skinner in the Hill Times

Columns

The PMPRB has outlived its usefulness: Nigel Rawson in the Hill Times

June 28, 2023

The Patented Medicine Prices Review Board is selling Canadians a lemon: Nigel Rawson for Inside Policy

Columns

Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail

March 17, 2023

The U.S. outsources control of drug prices to Canada: weird! Richard Owens in the Financial Post

Columns

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

March 1, 2023

Columns

For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

January 24, 2023

Page 1 of 2 1 2 Next

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

No Result

View All Result

Waiting for new drugs for rare disorders in Canada

Nigel Rawson

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

The PMPRB has outlived its usefulness: Nigel Rawson in the Hill Times

Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

For drug access, Canadians with rare disorders are 40 years behind Americans: Nigel Rawson and John Adams in the Financial Post

Top News

Canada-Poland partnership and the energy security of Europe

Gender diverse prisoners and sex-based patterns of offending

Is the ‘New Ottawa Consensus’ killing our economy?: Jon Hartley in the Hub

Multimedia

Zelenskyy visit: Balkan Devlen on CBC News

Romanian Energy Minister, Sebastian Burduja, talks energy security with Jonathan Berkshire Miller

Canada’s accusation against India: Jonathan Berkshire Miller on CBC News’ About That

What the new BRICS currency could mean for Canada: David Collins for Inside Policy

Leaked union call reveals details of parental rights counterprotest: Stuart Parker for Inside Policy

MLI Releases “Khalistan: A Project of Pakistan”: New MLI Publication By Terry Milewski

Airship ready, Canada should develop zeppelin technology for northern resource sector: Heather Exner-Pirot in the Globe and Mail

China is on a relentless mission to control Canada’s Arctic waters: Rob Huebert in the Globe and Mail

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us